Evidence map›Paper›PMID 36192750›Full record

ArticleLipids in health and disease2022

Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study.

Qi Liu, Huijie Dong, Yuzhu Li, Yingying Shen, Yilei Hong, Ying Chen, Shan Liu, Xiaolian Wu, Wenbin Liu, Huijin Hu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lipids in health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Qi Liu *The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Huijie Dong *The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuzhu LiThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yingying ShenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yilei HongThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ying ChenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Shan LiuDepartment of Clinical Evaluation Center, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xiaolian WuDepartment of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005), Zhejiang, People's Republic of China.
Wenbin LiuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Huijin HuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuechao ZhaoThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Shenyun LinThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yiping ShenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuhong ZhouThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Baodong YeThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. 13588453501@163.com.
Dijiong WuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. wudijiong@zcmu.edu.cn.

Funding

Health technology Plan of Zhejiang Province 2022RC216National Natural Science Foundation of China 82174138Zhejiang Scientific Research Fund of Traditional Chinese Medicine 2020ZB085Zhejiang Scientific Research Fund of Traditional Chinese Medicine 2022ZA059
6 · The paper itself

Abstract

backgroundAnti-thymoglobulin (ATG)-based immunosuppressive treatment (IST) is the standard first-line management for patients with severe AA/very severe AA (SAA/VSAA) and is not suitable for allogeneic stem cell transplantation. The response predictor was not fully investigated.

objectiveThe present study attempted to explore other characteristics, such as serum lipid changes, during ATG-based IST and analyzed their significance in predicting IST response and survival.

methodsA total of 61 newly diagnosed SAA/VSAA patients who received ATG-based IST were enrolled from January 2011 to June 2019. The blood lipid levels, immunoglobulins, and peripheral T lymphocytes were retrospectively collected, and their correlations with IST response, estimated 8.5-year overall survival (OS) and event-free survival (EFS) were analyzed.

resultsThe overall response (OR)/complete remission (CR) at 3, 6, and 9 months was 24.6%/6.6%, 52.5%/14.8%, and 65.6%/23.0%, respectively. Based on the 9-month response effect, patients were divided into IST-response (IST-R) and IST-nonresponse (IST-NR) groups. The subgroup baseline characteristics showed that the disease severity grade, absolute neutrophil granulocyte count (ANC), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein-A (Apo-A) differed between the IST-R and IST-NR groups. Patients with lower Apo-A (< 1.205 g/L) level pretreatment had a better event-free survival (EFS), and a moderate negative correlation was established between the pretreatment Apo-A and 9-month response (P = 0.004). In addition, the T-cell subset and immunoglobulin analyses showed that the responsive patients had a low serum IgA level, which decreased further after therapy. Additionally, a moderate negative correlation was established between the 3-month IgA and 9-month response (P = 0.006).

conclusionSerum Apo-A is a prognostic biomarker for newly diagnosed < 60-year-old SAA/VSAA patients who received ATG-based IST (registered at chictr.org.cn as # ChiCTR2100052979).

Indexed as

Anemia, AplasticApolipoproteinsApolipoproteins ABiomarkersCholesterol, LDLCyclosporineHumansImmunoglobulin AImmunosuppression TherapyImmunosuppressive AgentsLipoproteins, HDLMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeApolipoproteinsApolipoproteins ABiomarkersCholesterol, LDLCyclosporineImmunoglobulin AImmunosuppressive AgentsLipoproteins, HDLAplastic anemiaApolipoprotein-ABlood lipidImmune globulinT-cell subset

Identifiers

PMID36192750
PMCPMC9531379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.